During this conference, Exelixis and Ipsen management and invited guest speakers have reviewed and provided context of the results from the Cabosun study, along with the other data sets on cabozantinib.
This conference was held by and in presence of Prof. Dr. Choueiri, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and chair of the CABOSUN study (right on the picture).
Prof. Sumanta Pal, medical oncologist in Duarte, California
Prof. Dr. Nizar Tannir, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
Gisela Schwab, President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis
Click on this link to watch the conference
Click on this link to access the presentation